A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors (Q35563528)
Jump to navigation
Jump to search
scientific article published on 28 September 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors |
scientific article published on 28 September 2011 |
Statements
1 reference
A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors (English)
1 reference
T R Jeffry Evans
1 reference
Mark Middleton
1 reference
Jan H M Schellens
1 reference
Suzanne Leijen
1 reference
Patricia M M B Soetekouw
1 reference
Marianne Nicolson
1 reference
Maria Learoyd
1 reference
Lynda Grinsted
1 reference
Victoria Zazulina
1 reference
Thinn Pwint
1 reference
28 September 2011
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference